tiprankstipranks
Elevance Health, Inc. (ELV)
NYSE:ELV
US Market
ELV
Elevance Health
RESEARCH TOOLSreports
Want to see ELV full AI Analyst Report?

Elevance Health (ELV) Stock Forecast & Price Target

2,900 Followers
See the Price Targets and Ratings of:

ELV Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
14 Buy
5 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$409.79
▲(26.85% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $409.79 with a high forecast of $498.00 and a low forecast of $331.00. The average price target represents a 26.85% change from the last price of $323.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"269":"$269","384":"$384","499":"$499","326.5":"$326.5","441.5":"$441.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":498,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$498.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":409.78947368421046,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$409.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":331,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$331.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[269,326.5,384,441.5,499],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,402.66,409.99384615384616,417.3276923076923,424.6615384615385,431.99538461538464,439.3292307692308,446.6630769230769,453.9969230769231,461.33076923076925,468.6646153846154,475.9984615384615,483.3323076923077,490.66615384615386,{"y":498,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,402.66,403.2084210526316,403.75684210526316,404.30526315789473,404.8536842105263,405.40210526315786,405.95052631578943,406.49894736842106,407.0473684210526,407.5957894736842,408.14421052631576,408.6926315789473,409.2410526315789,{"y":409.78947368421046,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,402.66,397.14769230769235,391.6353846153846,386.12307692307695,380.6107692307692,375.09846153846155,369.5861538461539,364.07384615384615,358.5615384615385,353.0492307692308,347.5369230769231,342.0246153846154,336.5123076923077,{"y":331,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":369.167,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.194,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270.103,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.363,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.926,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":348.402,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.735,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.268,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372.68,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$498.00Average Price Target$409.79Lowest Price Target$331.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on ELV
Erin Wright
Morgan Stanley
Morgan Stanley
$352→$404
Hold
25.06%
Upside
Assigned
06/04/26
Elevance Health price target raised to $404 from $352 at Morgan StanleyElevance Health price target raised to $404 from $352 at Morgan Stanley
Wells Fargo Analyst forecast on ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$391
Buy
21.03%
Upside
Reiterated
06/04/26
Analysts Are Bullish on Top Healthcare Stocks: Elevance Health (ELV), Indivior (INDV)
Bank of America Securities Analyst forecast on ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$435→$460
Buy
42.39%
Upside
Reiterated
06/04/26
Bank of America Securities Remains a Buy on Elevance Health (ELV)
Truist Financial Analyst forecast on ELV
David S Macdonald
Truist Financial
Truist Financial
$375→$450
Buy
39.30%
Upside
Assigned
06/01/26
Elevance Health price target raised to $450 from $375 at TruistElevance Health price target raised to $450 from $375 at Truist
Bernstein Analyst forecast on ELV
Lance Wilkes
Bernstein
Bernstein
$424
Buy
31.25%
Upside
Reiterated
05/27/26
Bernstein Remains a Buy on Elevance Health (ELV)
Barclays Analyst forecast on ELV
Andrew Mok CFA
Barclays
Barclays
$408→$480
Buy
48.58%
Upside
Reiterated
05/26/26
Elevance Health price target raised to $480 from $408 at BarclaysElevance Health price target raised to $480 from $408 at Barclays
UBS Analyst forecast on ELV
A.J. Rice
UBS
UBS
$400→$460
Buy
42.39%
Upside
Reiterated
05/22/26
Elevance Health price target raised to $460 from $400 at UBSElevance Health price target raised to $460 from $400 at UBS
Deutsche Bank Analyst forecast on ELV
George Hill
Deutsche Bank
Deutsche Bank
$363→$498
Buy
54.16%
Upside
Upgraded
05/20/26
Elevance Health upgraded to Buy from Hold at Deutsche BankElevance Health upgraded to Buy from Hold at Deutsche Bank
Mizuho Securities Analyst forecast on ELV
Ann Hynes
Mizuho Securities
Mizuho Securities
$385→$435
Buy
34.65%
Upside
Reiterated
05/19/26
Elevance Health price target raised to $435 from $385 at MizuhoElevance Health price target raised to $435 from $385 at Mizuho
Evercore ISI Analyst forecast on ELV
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$360
Buy
11.44%
Upside
Upgraded
05/19/26
Elevance Health added to 'Tactical Outperform' list at Evercore ISIElevance Health added to 'Tactical Outperform' list at Evercore ISI
J.P. Morgan Analyst forecast on ELV
Lisa Gill
J.P. Morgan
J.P. Morgan
$397→$411
Buy
27.22%
Upside
Assigned
04/28/26
Elevance Health price target raised to $411 from $397 at JPMorganElevance Health price target raised to $411 from $397 at JPMorgan
Goldman Sachs Analyst forecast on ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$350→$370
Hold
14.53%
Upside
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Elevance Health (NYSE: ELV) and Eli Lilly & Co (NYSE: LLY)
TD Cowen Analyst forecast on ELV
Ryan Langston
TD Cowen
TD Cowen
$400
Buy
23.82%
Upside
Reiterated
04/24/26
Elevance Health: Strong Earnings Momentum and Attractive Valuation Support Buy Rating and $400 Target
Leerink Partners Analyst forecast on ELV
Whit Mayo
Leerink Partners
Leerink Partners
$357→$364
Hold
12.68%
Upside
Reiterated
04/23/26
Elevance Health price target raised to $364 from $357 at LeerinkElevance Health price target raised to $364 from $357 at Leerink
Guggenheim Analyst forecast on ELV
Jason Cassorla
Guggenheim
Guggenheim
$396→$399
Buy
23.51%
Upside
Reiterated
04/23/26
Guggenheim Remains a Buy on Elevance Health (ELV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on ELV
Erin Wright
Morgan Stanley
Morgan Stanley
$352→$404
Hold
25.06%
Upside
Assigned
06/04/26
Elevance Health price target raised to $404 from $352 at Morgan StanleyElevance Health price target raised to $404 from $352 at Morgan Stanley
Wells Fargo Analyst forecast on ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$391
Buy
21.03%
Upside
Reiterated
06/04/26
Analysts Are Bullish on Top Healthcare Stocks: Elevance Health (ELV), Indivior (INDV)
Bank of America Securities Analyst forecast on ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$435→$460
Buy
42.39%
Upside
Reiterated
06/04/26
Bank of America Securities Remains a Buy on Elevance Health (ELV)
Truist Financial Analyst forecast on ELV
David S Macdonald
Truist Financial
Truist Financial
$375→$450
Buy
39.30%
Upside
Assigned
06/01/26
Elevance Health price target raised to $450 from $375 at TruistElevance Health price target raised to $450 from $375 at Truist
Bernstein Analyst forecast on ELV
Lance Wilkes
Bernstein
Bernstein
$424
Buy
31.25%
Upside
Reiterated
05/27/26
Bernstein Remains a Buy on Elevance Health (ELV)
Barclays Analyst forecast on ELV
Andrew Mok CFA
Barclays
Barclays
$408→$480
Buy
48.58%
Upside
Reiterated
05/26/26
Elevance Health price target raised to $480 from $408 at BarclaysElevance Health price target raised to $480 from $408 at Barclays
UBS Analyst forecast on ELV
A.J. Rice
UBS
UBS
$400→$460
Buy
42.39%
Upside
Reiterated
05/22/26
Elevance Health price target raised to $460 from $400 at UBSElevance Health price target raised to $460 from $400 at UBS
Deutsche Bank Analyst forecast on ELV
George Hill
Deutsche Bank
Deutsche Bank
$363→$498
Buy
54.16%
Upside
Upgraded
05/20/26
Elevance Health upgraded to Buy from Hold at Deutsche BankElevance Health upgraded to Buy from Hold at Deutsche Bank
Mizuho Securities Analyst forecast on ELV
Ann Hynes
Mizuho Securities
Mizuho Securities
$385→$435
Buy
34.65%
Upside
Reiterated
05/19/26
Elevance Health price target raised to $435 from $385 at MizuhoElevance Health price target raised to $435 from $385 at Mizuho
Evercore ISI Analyst forecast on ELV
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
$360
Buy
11.44%
Upside
Upgraded
05/19/26
Elevance Health added to 'Tactical Outperform' list at Evercore ISIElevance Health added to 'Tactical Outperform' list at Evercore ISI
J.P. Morgan Analyst forecast on ELV
Lisa Gill
J.P. Morgan
J.P. Morgan
$397→$411
Buy
27.22%
Upside
Assigned
04/28/26
Elevance Health price target raised to $411 from $397 at JPMorganElevance Health price target raised to $411 from $397 at JPMorgan
Goldman Sachs Analyst forecast on ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$350→$370
Hold
14.53%
Upside
Reiterated
04/24/26
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (NYSE: TMO), Elevance Health (NYSE: ELV) and Eli Lilly & Co (NYSE: LLY)
TD Cowen Analyst forecast on ELV
Ryan Langston
TD Cowen
TD Cowen
$400
Buy
23.82%
Upside
Reiterated
04/24/26
Elevance Health: Strong Earnings Momentum and Attractive Valuation Support Buy Rating and $400 Target
Leerink Partners Analyst forecast on ELV
Whit Mayo
Leerink Partners
Leerink Partners
$357→$364
Hold
12.68%
Upside
Reiterated
04/23/26
Elevance Health price target raised to $364 from $357 at LeerinkElevance Health price target raised to $364 from $357 at Leerink
Guggenheim Analyst forecast on ELV
Jason Cassorla
Guggenheim
Guggenheim
$396→$399
Buy
23.51%
Upside
Reiterated
04/23/26
Guggenheim Remains a Buy on Elevance Health (ELV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months
Lisa GillJ.P. Morgan
Success Rate
11/16 ratings generated profit
69%
Average Return
+3.24%
Copying Lisa Gill's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +3.24% per trade.
1 Year
A.J. RiceUBS
Success Rate
24/31 ratings generated profit
77%
Average Return
+18.74%
Copying A.J. Rice's trades and holding each position for 1 Year would result in 77.42% of your transactions generating a profit, with an average return of +18.74% per trade.
2 Years
A.J. RiceUBS
Success Rate
27/31 ratings generated profit
87%
Average Return
+38.91%
Copying A.J. Rice's trades and holding each position for 2 Years would result in 87.10% of your transactions generating a profit, with an average return of +38.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
22
26
25
31
30
Hold
7
5
9
9
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
31
34
40
39
In the current month, ELV has received 30 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 409.79.
Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $6.20 with a range of $6.00 to $6.73. The previous quarter’s EPS was $12.58. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s earnings estimate for ELV is $6.20 with a range of $6.00 to $6.73. The previous quarter’s EPS was $12.58. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $48.80B with a range of $47.58B to $49.66B. The previous quarter’s sales results were $50.18B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s sales forecast for ELV is $48.80B with a range of $47.58B to $49.66B. The previous quarter’s sales results were $50.18B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health, Inc.’s 12-month average price target is 409.79.
    What is ELV’s upside potential, based on the analysts’ average price target?
    Elevance Health, Inc. has 26.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ELV a Buy, Sell or Hold?
          Elevance Health, Inc. has a consensus rating of Moderate Buy which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Elevance Health, Inc.’s price target?
            The average price target for Elevance Health, Inc. is 409.79. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $498.00 ,the lowest forecast is $331.00. The average price target represents 26.85% Increase from the current price of $323.05.
              What do analysts say about Elevance Health, Inc.?
              Elevance Health, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of ELV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.